What was recalled
The U.S. Food and Drug Administration (FDA) has issued a Class II recall involving a specific pharmaceutical product distributed by IntegraDose Compounding Services LLC. This recall is significant because it involves a potent medication used in clinical settings, requiring careful attention to detail from healthcare providers and patients alike. The company responsible for this product is located at 3650 Victorie St N, Suite 900, in Shoreview, Minnesota. It is important to note that while the manufacturer’s headquarters are in Minnesota, the distribution pattern of this recalled item was nationwide, meaning it could potentially be found in medical facilities or pharmacies across all fifty states.
The specific product at the center of this recall is fentaNYL Citrate, formulated as a Sterile CADD for Injection. This medication is packaged in Sterile Water and has a precise concentration of 2,2500 mcg per 50mL. The brand name associated with this product is IntegraDose. For those who need to verify the exact item, the National Drug Code (NDC) is 71139-6030-1. This unique identifier is critical for pharmacists and hospital inventory managers to immediately locate any affected stock in their systems.
Furthermore, this recall applies strictly to a specific lot of the product. The affected lot number is 20260310FEN-1. The expiration date for this particular batch is listed as September 6, 2026. Because recalls are often lot-specific, it is vital to check the physical packaging or digital inventory records against this exact lot number and expiration date. Products from other lots with different expiration dates are not part of this specific FDA action.
The decision to issue a Class II recall indicates that the use of this product may cause temporary health problems or pose a slight threat of a serious nature, though it is unlikely to result in serious adverse health consequences. This classification underscores the importance of verifying the product details immediately. IntegraDose Compounding Services LLC initiated this recall on May 12, 2026. Healthcare professionals should review their current inventory of fentaNYL Citrate Sterile CADD for Injection against the details provided above to ensure patient safety and regulatory compliance.
The hazard, explained
At the heart of this FDA recall is a critical issue known as a "subpotent drug." In plain terms, this means that the medication in question contains less of the active ingredient than it claims to have on its label. For fentanyl citrate, a powerful synthetic opioid used for pain management, precision is not just a matter of convenience—it is a matter of life and death. The specific product involved, IntegraDose Compounding Services LLC’s fentaNYL Citrate, Sterile CADD for Injection (NDC 71139-6030-1), was intended to deliver a precise concentration of 2,250 mcg per 50 mL. However, testing revealed that the actual potency fell below this required standard.
To understand why this is dangerous, it helps to look at how fentanyl works in the body. Fentanyl is an extremely potent synthetic opioid analgesic, estimated to be up to 100 times more potent than morphine. It functions by binding to mu-opioid receptors in the brain and spinal cord, effectively blocking pain signals and producing a calming, euphoric effect. Because its therapeutic window—the range between an effective dose and a toxic one—is so narrow, healthcare providers rely on exact dosing calculations when administering it via CADD (Controlled Addition Drug Delivery) pumps. These pumps are designed to deliver medication at a steady, predictable rate over time.
When a drug is subpotent, the physical mechanism of failure lies in the discrepancy between the prescribed dose and the actual amount of drug molecules entering the patient’s bloodstream. If a clinician programs a pump to deliver 100 mcg of fentanyl based on the label’s concentration, but the vial actually contains only 80 mcg worth of active drug due to subpotency, the patient receives a significant underdose. This can lead to inadequate pain control, forcing providers to increase the infusion rate or give additional bolus doses in an attempt to achieve relief. This reactive adjustment creates a volatile situation where the patient’s system is subjected to fluctuating and unpredictable levels of the drug.
The danger here is twofold. First, the immediate risk is that the patient does not receive the necessary pain relief, which can cause severe physiological stress, anxiety, and complications related to unmanaged pain, particularly in post-surgical or intensive care settings. Second, and perhaps more critically, the attempt to correct an underdose by increasing the infusion rate can inadvertently lead to accidental overdose if the provider is unaware of the subpotency issue. If the pump is adjusted upward based on the assumption that the concentration is correct, but the drug’s actual pharmacokinetics are altered or if there is any subsequent variability in absorption, the patient may quickly exceed safe thresholds. Given fentanyl’s rapid onset and high potency, even small errors in calculation can result in respiratory depression, where breathing slows down dangerously or stops entirely, leading to hypoxia, brain damage, or death.
This type of hazard is particularly insidious because it does not present with obvious physical defects like a broken seal or discoloration. The vial may look perfect, and the liquid may appear clear and correct. The error is invisible to the naked eye, relying entirely on laboratory analysis to detect. This makes the recall vital for healthcare professionals who must immediately stop using the affected lots until they can verify the potency through alternative means or obtain replacement stock from a verified source.
Who is most at risk
When we talk about a Class II recall involving fentanyl citrate for injection, it is important to understand that the primary group at immediate risk is not the general public walking down the street, but rather patients receiving specialized medical care in hospitals, clinics, or home health settings. Fentanyl is an extremely potent synthetic opioid analgesic, typically reserved for managing severe pain that cannot be controlled by other medications. Because this product was distributed nationwide to healthcare providers and compounding pharmacies, the individuals most vulnerable to harm are those who have been prescribed this specific medication for acute or chronic pain management, post-surgical recovery, or palliative care.
The core danger here stems from the nature of the defect: the drug is subpotent. This means that the actual concentration of fentanyl in the CADD (Chronic Ambulatory Drug Delivery) cartridge is lower than what is stated on the label. For patients relying on this medication, particularly those using portable infusion pumps to deliver a steady dose of pain relief over time, this discrepancy can be critical. If a patient’s body has become accustomed to a certain level of opioid effect, receiving less medication than expected can lead to uncontrolled pain (breakthrough pain) or withdrawal-like symptoms. For elderly patients or those with compromised respiratory function, the stress of severe, untreated pain can exacerbate existing health conditions, leading to complications such as increased blood pressure, heart strain, or anxiety-induced respiratory distress.
While the risk of overdose is typically associated with too much medication, a subpotent drug presents a different set of risks. Healthcare providers may attempt to compensate for the lack of effect by increasing the infusion rate or prescribing additional rescue doses. This adjustment process creates a window of vulnerability where the patient’s pain management plan becomes unstable and unpredictable. Patients who are dependent on opioids or those with a history of substance use disorder may find themselves in a precarious position, struggling to maintain stability while their prescribed treatment fails to deliver the promised therapeutic level.
Furthermore, because this product is intended for injection via a CADD pump, it is designed for continuous delivery. This means that any inconsistency in potency affects the patient over an extended period, not just during a single dose. Individuals with limited mobility or those living alone may be at higher risk if they experience sudden changes in their pain levels or physical well-being due to the under-dosing, as they may have reduced access to immediate medical assistance. It is also worth noting that while the recall affects a specific lot and expiry date, any patient who received this product from IntegraDose Compounding Services LLC during the distribution window should be considered potentially affected, regardless of their current symptom status, because the inconsistency in the drug's strength cannot be verified without laboratory testing.
How to tell if you have the recalled item
Identifying whether a specific medication is part of this FDA recall requires careful attention to several distinct details printed on the packaging and labeling. Because fentanyl is a potent opioid analgesic used in clinical settings, it is typically distributed through specialized medical channels rather than standard retail pharmacies. If you are a healthcare provider, nurse, or patient managing home infusion therapy, you must verify the product against the official recall notice by checking multiple data points simultaneously. Relying on just one piece of information can lead to confusion, so we will walk you through exactly what to look for and where to find it.
First and foremost, check the brand name printed on the label or packaging. The recalled product is explicitly identified as being manufactured by IntegraDose Compounding Services LLC. You should see "IntegraDose" clearly displayed as the brand identifier. If the product bears a different manufacturer’s name, it is not part of this specific recall action, although you should always verify the source of any compounded medication.
Next, examine the drug description and concentration. The recalled item is fentaNYL Citrate, Sterile CADD for Injection. It is crucial to note the exact strength: 2,2500 mcg/50mL in Sterile Water. This specific concentration is vital because fentanyl comes in various strengths for different clinical applications. If your product has a different microgram per milliliter ratio or is formulated in a different solution, it is not the recalled batch.
The National Drug Code (NDC) is your most reliable unique identifier. Look for NDC 71139-6030-1 on the label. This code is typically found on the front or side of the box and on the individual vial or bag label. Ensure all digits match exactly; even a single digit error means the product is not part of this recall.
You must also check the Lot Number and Expiration Date. The specific lot affected by this Class II recall is 20260310FEN-1. Locate the expiration date on the label, which should read 09/06/2026. If your product has a different lot number or an expiration date outside of this range, it is not included in this recall.
Finally, consider the distribution pattern and location. This recall affects products distributed nationwide, but the manufacturer is located at 3650 Victorie St N, Suite 900, Shoreview, MN. If you are unsure about the origin or have questions about the product’s provenance, contact your supplier or healthcare provider immediately with these details in hand. Do not use the medication until you have confirmed it is not part of this recall.
What to do — step by step
If you are a healthcare provider, pharmacist, or facility manager who may have received the recalled IntegraDose Compounding Services LLC fentaNYL Citrate for injection, it is critical to act immediately. Because this recall involves a subpotent drug—a medication that contains less of the active ingredient than it claims on the label—the risk is not immediate toxicity, but rather inadequate pain control or treatment efficacy. This can lead to serious clinical complications for patients who rely on precise dosing for anesthesia, acute pain management, or chronic conditions. While the official recall notice from the FDA does not explicitly state a specific return address or refund procedure in the provided text, standard protocol for Class II drug recalls requires immediate cessation of use and isolation of the product to prevent accidental administration.
- Stop Use Immediately: If you have any inventory of fentaNYL Citrate, Sterile CADD for Injection (2,2500 mcg/50mL in Sterile Water) with Lot number 20260310FEN-1 and NDC 71139-6030-1, remove it from your shelves and clinical workflow right now. Do not attempt to verify potency yourself or use the product for a "test dose." The hazard is inherent in the manufacturing or compounding process, meaning every unit in that lot is potentially compromised. Isolating the product prevents any nurse, physician, or patient from accidentally administering an insufficient dose.
- Contact the Distributor or Manufacturer: Reach out to IntegraDose Compounding Services LLC to report your possession of this specific lot. Since the remedy details are not explicitly outlined in the general recall summary, you must contact them directly to receive instructions on how to return the product or obtain a replacement. They are located at 3650 Victorie St N, Suite 900, Shoreview, MN. Ask specifically for their recall coordinator and request a written protocol for disposal or return. Do not dispose of the medication in regular trash or sewage until you have confirmed with them whether they require physical return for analysis or if they authorize on-site destruction under supervision.
- Notify Your Clinical Team: Inform all relevant staff members, including pharmacists, anesthesiologists, and nursing supervisors, about the recall. Provide them with the specific Lot number (20260310FEN-1) and Expiration Date (09/06/2026) so they can cross-reference their records. If any doses from this lot have already been administered to patients, you must review those patient charts carefully. While a subpotent drug is less likely to cause an overdose, it may result in breakthrough pain or insufficient sedation. Document the incident and monitor the affected patients for signs that their treatment plan needs adjustment.
- Document Your Actions: Keep a clear record of when you identified the product, when you removed it from service, and all communications with IntegraDose Compounding Services LLC. This documentation is vital for your facility’s compliance audits and ensures that you have proof of due diligence in protecting patient safety during this recall.
Remember, while the remedy steps are not fully detailed in the initial FDA announcement, the burden is on the holder of the product to ensure it does not reach a patient. Prompt action protects your patients from undertreatment and keeps your facility compliant with federal safety standards.
Your refund, repair, or replacement options
When a pharmaceutical product is recalled, particularly one involving a compounded medication like fentanyl citrate, the process for resolving your specific situation can feel somewhat opaque compared to recalling a consumer electronics device or a car part. In this instance, the recall notice from the Food and Drug Administration (FDA) regarding IntegraDose Compounding Services LLC does not explicitly detail the standard remedies of a refund, repair, or direct replacement in its public summary. This absence of specific logistical instructions is not uncommon for Class II drug recalls, which often focus on containment and risk mitigation rather than consumer-facing restitution. However, this does not mean you are left without recourse. The primary "remedy" in these scenarios is the immediate cessation of use and the safe disposal or return of the product to prevent any further harm. Because the recall involves a potent opioid analgesic that was found to be subpotent—meaning it may contain less active ingredient than labeled—the priority is ensuring the product does not remain in circulation or in your possession.
If you are a healthcare facility, pharmacy, or distributor that currently holds this specific lot of IntegraDose Compounding Services LLC fentanyl citrate (NDC 71139-6030-1, Lot 20260310FEN-1), the standard procedure for Class II recalls involves coordinating directly with the firm responsible for the distribution. While the recall facts do not list a specific customer service hotline or return address for consumers, they provide the manufacturer's physical location at 3650 Victorie St N, Suite 900, Shoreview, MN. In practice, entities affected by this recall are expected to contact IntegraDose Compounding Services LLC directly to arrange for the return of the product or to receive instructions on proper disposal through a licensed pharmaceutical waste handler. It is critical not to attempt to use any remaining stock from this lot, as the subpotency issue could lead to inadequate pain management or other clinical complications.
For individual patients who may have received this medication prior to the recall date of May 12, 2026, the path to resolution is typically managed through your prescribing physician or the dispensing pharmacy. These healthcare professionals act as the bridge between you and the manufacturer. They are responsible for notifying the firm of the issue and facilitating any necessary replacement therapy with a different, non-recalled lot from a different manufacturer or a different batch that has passed quality control. If you have questions about how to proceed with your specific prescription, do not hesitate to contact IntegraDose Compounding Services LLC at their provided Shoreview address or consult your healthcare provider for guidance on alternative treatment options. The goal is to ensure your medical needs are met safely while removing the subpotent product from the supply chain.
- Contact the Manufacturer: Reach out to IntegraDose Compounding Services LLC at 3650 Victorie St N, Suite 900, Shoreview, MN, for specific return or disposal instructions if you are a distributor or facility.
- Consult Your Provider: Patients should speak with their doctor or pharmacist to arrange for alternative medication, as direct refunds are not typically issued for compounded drugs.
- Do Not Use the Product: Stop using any fentanyl citrate from Lot 20260310FEN-1 immediately due to the subpotency hazard.
What can happen if you ignore it
When a pharmaceutical product is recalled due to being subpotent, the danger lies not in immediate toxicity, but in the dangerous gap between what a patient expects and what they actually receive. Fentanyl citrate is an opioid analgesic with an extremely narrow therapeutic index, meaning the difference between a dose that effectively manages severe pain and one that causes respiratory depression or death is very small. In this specific recall, IntegraDose Compounding Services LLC identified that their Sterile CADD for Injection, specifically lot 20260310FEN-1, contains less fentanyl than the label claims. If you continue to use this product while believing it is providing the prescribed strength, you are essentially operating in a state of medical uncertainty that can have life-altering consequences.
The primary risk of ignoring a subpotent drug recall is therapeutic failure. Because the medication contains less active ingredient than advertised, it may fail to control pain adequately. For patients relying on fentanyl for post-surgical recovery, cancer-related pain, or other severe chronic conditions, this can lead to uncontrolled suffering and physiological stress. More critically, in an attempt to alleviate their pain, a patient or caregiver might administer additional doses of the same subpotent medication, assuming it is not working. This creates a complex dosing scenario where the total volume of fluid infused increases, but the actual amount of opioid delivered remains unpredictable and insufficient. This delay in effective pain management can hinder recovery, increase anxiety, and strain the body’s systems unnecessarily.
However, the most severe potential consequence involves the clinical response to this failure. If a healthcare provider or patient determines that the current infusion is ineffective due to the subpotency error, there is a risk of abruptly stopping the medication or attempting to rapidly titrate up with other opioids without proper medical supervision. Sudden changes in opioid regimens can lead to withdrawal symptoms, which are physically distressing and can cause severe dehydration, hypertension, and cardiac stress. Furthermore, if the subpotent product leads to inadequate pain control during a critical procedure or recovery period, it can increase the risk of complications such as blood clots, pneumonia, or prolonged hospital stays due to immobility.
Additionally, using recalled compounding drugs bypasses the safety net of quality assurance. The FDA classifies this as a Class II recall because while the products are not likely to cause serious adverse health consequences, they are defective in a way that undermines trust and safety protocols. Ignoring the recall means you are continuing to use a product from a specific manufacturing run (lot 20260310FEN-1) where quality control failed. This not only jeopardizes your immediate treatment but also contributes to the broader issue of medication integrity. By not returning or destroying the product, you risk accidentally using it in the future after the recall notice has faded from memory, potentially exposing yourself or others to the same subpotency risks later on. The safest path is to act immediately to ensure your medical team can adjust your treatment plan with known, verified, and potent alternatives.
Staying safe: broader tips
When we talk about pharmaceutical safety, particularly regarding compounded medications like the fentanyl citrate involved in this recall, it is easy to feel overwhelmed by the specifics of lot numbers and distribution patterns. However, building a resilient approach to medication safety starts with habits that apply to all prescription drugs, not just those subject to a specific alert. The most powerful tool you have is consistent communication with your healthcare providers. Always ask questions about new medications, including how they are made, who makes them, and what to look for in terms of physical changes. If you receive a medication from a compounding pharmacy, do not hesitate to verify the facility’s registration status with the FDA and your state board of pharmacy. These facilities operate under different regulations than standard manufacturers, so knowing their background gives you an extra layer of confidence.
Another critical aspect of staying safe is understanding how to store your medications properly. Many drugs, especially those prepared in sterile environments for specific delivery systems like CADD pumps, are sensitive to temperature, light, and humidity. Improper storage can degrade a medication even if it has not been recalled, leading to subpotent or ineffective treatment. Keep your medications in their original packaging until use, store them at the temperatures recommended by the pharmacist, and never share prescription drugs with others. This is especially important for controlled substances like fentanyl, which carry high risks of misuse and accidental ingestion.
Regularly checking for updates on drug recalls is also a proactive step that many people overlook. You can sign up for email alerts from the FDA’s MedWatch program or visit their website periodically to see if any products you use have been pulled from the market. This does not mean you should panic; it means you are informed. If you notice unusual changes in your medication—such as discoloration, particles, or strange odors—stop using it immediately and contact your pharmacist. Trust your instincts. Your body knows when something is wrong, and early detection of potential issues can prevent serious harm.
Finally, remember that safety is a shared responsibility. Pharmacists, doctors, manufacturers, and regulators all play a part, but you are the final checkpoint in your own care. By staying informed, asking questions, and following storage guidelines, you take control of your health journey. This approach not only protects you from specific recalls but also builds a foundation for lifelong medication safety. Stay curious, stay cautious, and never underestimate the power of being an active participant in your healthcare.